Clostridium difficile-associated diarrhea - The new scourge of the health care facility

Canadian Journal of Infectious Diseases

Volumn 11, Issue 1, 2000, Pages 25-27

  Conly, J M ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULFONAMIDE; TIMENTIN; TROVAFLOXACIN; VANCOMYCIN;

BACTERIAL COLONIZATION; BACTERIUM ISOLATION; CLOSTRIDIUM DIFFICILE; COLITIS; DIARRHEA; DOSE RESPONSE; HEALTH CARE FACILITY; HOSPITAL INFECTION; HUMAN; NONHUMAN; NOTE;

EID: 0034057346     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/608154     Document Type: Note

References (22)

1. Barbut F, Corthier G, Charpak Y, et al. Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study. Arch Intern Med 1996;156:1449-54.
2. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16:459-77.
3. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997;92:739-50.
4. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial. Ann Intern Med 1992;117:297-302.
5. Johnson S, Clabots CR, Linn FV, Olson MM, Peterson LR, Gerding DN. Nosocomial Clostridium difficile colonisation and disease. Lancet 1990;336:97-100.
6. Gerding DN. Clostridium difficile-associated disease: a persistently plaguing problem. APU Newsletter 1996;14:1-6.
7. Shim JK, Johnson S, Samore MH, Bliss DZ, Gerding DN. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998;351:633-6.
8. Anand A, Bashey B, Mir T, Glatt AE. Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 1994;89:519-23.
9. Yip C, Salama S, Olde J, et al. Ouinolone use was a risk factor for nosocomial Clostridium difficile-associated diarrhea. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999. [Abst 742]
10. Hernandez F, Khorana AA, Scott JD, Feuerstein S, Forrest A, Freer JP. Incidence of Clostridium difficile colitis in patients treated with antibiotics in a community hospital setting. 9th Annual Scientific Meeting on the Society for Healthcare Epidemiology of America, San Francisco, April 18 to 20, 1999. [Abst 34]
11. Hirschhorn LR, Trnka Y, Onderdonk A, Lee ML, Platt R. Epidemiology of community-acquired Clostridium difficile-associated diarrhea. J Infect Dis 1994;169:127-33.
12. Clabots CR, Johnson S, Olson MM, Peterson LR, Gerding DN. Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis 1992;166:561-7.
13. Miller MA, Hyland M, Ofner, M, Gourdeau M, Ishak M, the Canadian Hospital Epidemiology Committee, and the Canadian Nosocomial Infection Surveillance Program, Health Canada. Morbidity, mortality, and health-care burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. 8th Annual Scientific Meeting of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1998;19:691. [Abst 65]
14. Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol 1994;15:371-81.
15. Manian FA, Meyer L. CDAD rates. Infect Control Hosp Epidemiol 1995;16:63-5.
16. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994;330:257-62.
17. Gardam MA, McCabe N, Hurn D, Dedier H, Garcia M, Conly JM. Association of nursing workload and bed closures on nosocomial transmission of vancomycin-resistant enterococci and Clostridium difficile. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26 to 29, 1999. [Abst 2085]
18. Pothoulakis C. Pathogenesis of Clostridium difficle-associated diarrhea. Eur J Gastroenterol Hepatology 1996;8:1041-7.
19. Depitre C, Delmee M, Avesani V, et al. Serogroup F strains of Clostridium difficile produce toxin B but not toxin A. J Med Microbiol 1993;38;434-41.
20. Embil J, Al-Barrak A, Alfa M, Dyck B, Olekson K, Nicoll D, et al. The one year experience following an outbreak of toxin A(-), toxin B(+) Clostridium difficile associated disease (CDAD) in a Canadian tertiary care center. 67th Conjoint Meeting on Infectious Diseases in conjunction with The Canadian Infectious Disease Society Annual Meeting, Edmonton, Alberta, October 31 to November 4, 1999. Can J Infect Dis 1999;10(Suppl D):85D. [Abst SP7]
21. Alfa MJ, Lyerly D, Neville L, et al. Characterization of a toxin A(-), toxin B(+) Clostridium difficile strain that caused a diarrhea outbreak in a Canadian tertiary care hospital. 67th Conjoint Meeting on Infectious Diseases in conjunction with The Canadian Infectious Disease Society Annual Meeting, Edmonton, Alberta, October 31 to November 4, 1999. Can J Infect Dis 1999;10(Suppl D):31D. [Abst E2]
22. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994;271:1913-8.